BioSpace News Archive

Vallon Pharmaceuticals, Inc. announced the pricing of its initial public offering of 2,250,000 shares of its common stock at a public offering price of $8.00 per share, for gross proceeds of $18.0 million, before deducting underwriting discounts, commissions and offering expenses.

Enlivex Therapeutics Ltd. announced that due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 2,296,107 ordinary shares, par value NIS 0.40 per share, of the Company at a price to the public of $20.00 per ordinary share, less underwriting discounts and commissions.

James Priour promoted to Chief Commercial Officer, added to Zymeworks’ Executive Committee John Babcook recognized as Distinguished Fellow

Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 500,000 ordinary shares, par value NIS 0.40 per share, of the Company at a price to the public of $20.00 per share.

Following Priority Review Libtayo receives full approval in locally advanced basal cell carcinoma (BCC) and accelerated approval in metastatic BCC Libtayo now approved for patients with advanced stages of the two most common skin cancers in the U.S. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sano

Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today confirmed that it has received a notice from Tang Capital Partners, LP

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2020 financial results after market close on Tuesday, March 2, 2021.

Total Revenues of $42.7 Million, up 11% Year-over-Year; Subscription Revenues of $31.4 Million, up 12% Year-over-Year

Precision Optics Corporation, Inc. (OTCQB: PEYE) (the “Company”) today announced that it has scheduled a conference call to discuss second quarter fiscal year 2021 financial results on Tuesday, February 16, 2021 at 5:00pm ET .

Nanoform Finland Plc and Herantis Pharma Plc announced that they have signed a Biologics Proof of Concept Agreement for formulation Proof of Concept projects aiming to enhance nasal drug delivery to the brain of Herantis’ CDNF therapies for Parkinson’s disease using Nanoform’s proprietary biological nanoparticle technology.